55,000 Shares in Zoetis Inc. $ZTS Purchased by Inspire Trust Co. N.A.

Inspire Trust Co. N.A. acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the 3rd quarter, HoldingsChannel.com reports. The firm acquired 55,000 shares of the company’s stock, valued at approximately $3,841,000.

Other large investors have also made changes to their positions in the company. Bahl & Gaynor LLC acquired a new stake in Zoetis during the 3rd quarter worth about $352,000. Philadelphia Trust Co. lifted its holdings in shares of Zoetis by 60.5% in the 3rd quarter. Philadelphia Trust Co. now owns 6,426 shares of the company’s stock valued at $449,000 after buying an additional 2,423 shares during the period. Confluence Wealth Services Inc. lifted its holdings in shares of Zoetis by 33.9% in the 3rd quarter. Confluence Wealth Services Inc. now owns 17,676 shares of the company’s stock valued at $1,234,000 after buying an additional 4,471 shares during the period. Marathon Wealth Advisors LLC acquired a new position in shares of Zoetis in the 3rd quarter valued at about $842,000. Finally, DMKC Advisory Services LLC purchased a new stake in shares of Zoetis in the third quarter worth about $3,166,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.2%

Shares of Zoetis stock opened at $82.48 on Wednesday. The firm has a 50-day simple moving average of $75.88 and a two-hundred day simple moving average of $92.18. The company has a market cap of $33.51 billion, a P/E ratio of 14.03, a price-to-earnings-growth ratio of 1.19 and a beta of 0.67. Zoetis Inc. has a fifty-two week low of $68.77 and a fifty-two week high of $132.49. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.24. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the prior year, the company posted $1.70 EPS. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. As a group, equities analysts predict that Zoetis Inc. will post 6.29 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.6%. Zoetis’s dividend payout ratio is presently 36.05%.

Wall Street Analyst Weigh In

Several research firms recently commented on ZTS. Citigroup dropped their target price on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. TD Cowen reduced their price target on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Piper Sandler decreased their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, August 10th. Cantor Fitzgerald set a $94.00 price objective on Zoetis in a research report on Tuesday, August 25th. Finally, JPMorgan Chase & Co. lowered their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $101.25.

Zoetis Profile

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.